Literature DB >> 23648371

Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters.

Lishui Cheng1, Robert F Hobbs, Paul W Segars, George Sgouros, Eric C Frey.   

Abstract

In radiopharmaceutical therapy, an understanding of the dose distribution in normal and target tissues is important for optimizing treatment. Three-dimensional (3D) dosimetry takes into account patient anatomy and the nonuniform uptake of radiopharmaceuticals in tissues. Dose-volume histograms (DVHs) provide a useful summary representation of the 3D dose distribution and have been widely used for external beam treatment planning. Reliable 3D dosimetry requires an accurate 3D radioactivity distribution as the input. However, activity distribution estimates from SPECT are corrupted by noise and partial volume effects (PVEs). In this work, we systematically investigated OS-EM based quantitative SPECT (QSPECT) image reconstruction in terms of its effect on DVHs estimates. A modified 3D NURBS-based Cardiac-Torso (NCAT) phantom that incorporated a non-uniform kidney model and clinically realistic organ activities and biokinetics was used. Projections were generated using a Monte Carlo (MC) simulation; noise effects were studied using 50 noise realizations with clinical count levels. Activity images were reconstructed using QSPECT with compensation for attenuation, scatter and collimator-detector response (CDR). Dose rate distributions were estimated by convolution of the activity image with a voxel S kernel. Cumulative DVHs were calculated from the phantom and QSPECT images and compared both qualitatively and quantitatively. We found that noise, PVEs, and ringing artifacts due to CDR compensation all degraded histogram estimates. Low-pass filtering and early termination of the iterative process were needed to reduce the effects of noise and ringing artifacts on DVHs, but resulted in increased degradations due to PVEs. Large objects with few features, such as the liver, had more accurate histogram estimates and required fewer iterations and more smoothing for optimal results. Smaller objects with fine details, such as the kidneys, required more iterations and less smoothing at early time points post-radiopharmaceutical administration but more smoothing and fewer iterations at later time points when the total organ activity was lower. The results of this study demonstrate the importance of using optimal reconstruction and regularization parameters. Optimal results were obtained with different parameters at each time point, but using a single set of parameters for all time points produced near-optimal dose-volume histograms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23648371      PMCID: PMC4151254          DOI: 10.1088/0031-9155/58/11/3631

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  28 in total

Review 1.  Radiotherapy with internal emitters: what can dosimetrists offer?

Authors:  Michael G Stabin
Journal:  Cancer Biother Radiopharm       Date:  2003-08       Impact factor: 3.099

Review 2.  Dosimetry of internal emitters.

Authors:  George Sgouros
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

3.  Fast modelling of the collimator-detector response in Monte Carlo simulation of SPECT imaging using the angular response function.

Authors:  X Song; W P Segars; Y Du; B M W Tsui; E C Frey
Journal:  Phys Med Biol       Date:  2005-04-06       Impact factor: 3.609

4.  Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture.

Authors:  A Niemierko; M Goitein
Journal:  Radiother Oncol       Date:  1991-03       Impact factor: 6.280

Review 5.  Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.

Authors:  Malik E Juweid
Journal:  J Nucl Med       Date:  2002-11       Impact factor: 10.057

Review 6.  Preclinical and clinical studies of peptide receptor radionuclide therapy.

Authors:  Stefan E Pool; Eric P Krenning; Gerben A Koning; Casper H J van Eijck; Jaap J M Teunissen; Boen Kam; Roelf Valkema; Dik J Kwekkeboom; Marion de Jong
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

7.  131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Peter L Roberson; Scott J Wilderman; Hanan Amro; Denise D Regan; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

8.  A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy.

Authors:  Robert F Hobbs; Todd McNutt; Sébastien Baechler; Bin He; Caroline E Esaias; Eric C Frey; David M Loeb; Richard L Wahl; Ori Shokek; George Sgouros
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

9.  Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.

Authors:  Yuni K Dewaraja; Scott J Wilderman; Michael Ljungberg; Kenneth F Koral; Kenneth Zasadny; Mark S Kaminiski
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

10.  Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.

Authors:  Andrew R Prideaux; Hong Song; Robert F Hobbs; Bin He; Eric C Frey; Paul W Ladenson; Richard L Wahl; George Sgouros
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more
  6 in total

1.  Repeatability of Radiotracer Uptake in Normal Abdominal Organs with ¹¹¹In-Pentetreotide Quantitative SPECT/CT.

Authors:  Steven P Rowe; Esther Vicente; Nadège Anizan; Hao Wang; Jeffrey P Leal; Martin A Lodge; Eric C Frey; Richard L Wahl
Journal:  J Nucl Med       Date:  2015-05-14       Impact factor: 10.057

2.  Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Jincheng Shen; Lauren B Smith; Jure Murgic; Hatice Savas; Ehab Youssef; Denise Regan; Scott J Wilderman; Peter L Roberson; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2014-05-19       Impact factor: 10.057

3.  A no-gold-standard technique for objective assessment of quantitative nuclear-medicine imaging methods.

Authors:  Abhinav K Jha; Brian Caffo; Eric C Frey
Journal:  Phys Med Biol       Date:  2016-03-16       Impact factor: 3.609

4.  What You See Is Not What You Get: On the Accuracy of Voxel-Based Dosimetry in Molecular Radiotherapy.

Authors:  Johannes Tran-Gia; Maikol Salas-Ramirez; Michael Lassmann
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 10.057

5.  Development and evaluation of convergent and accelerated penalized SPECT image reconstruction methods for improved dose-volume histogram estimation in radiopharmaceutical therapy.

Authors:  Lishui Cheng; Robert F Hobbs; George Sgouros; Eric C Frey
Journal:  Med Phys       Date:  2014-11       Impact factor: 4.071

6.  MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.

Authors:  Yuni K Dewaraja; Michael Ljungberg; Alan J Green; Pat B Zanzonico; Eric C Frey; Wesley E Bolch; A Bertrand Brill; Mark Dunphy; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels
Journal:  J Nucl Med       Date:  2013-10-15       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.